Back to Search
EDWARD SAUSVILLE, M.D.
M.D.
Medical Oncology Physician
NPI: 1528020393Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D27992(MD)
Research & Publications (20)
Contributions of human tumor xenografts to anticancer drug development.
PMID 16585151·Cancer Res·2006
6-review
Cell cycle regulatory kinase modulators: interim progress and issues.
PMID 16248786·Curr Top Med Chem·2005
6-review
Optimizing target selection and development strategy in cancer treatment: the next wave.
PMID 15379701·Curr Med Chem Anticancer Agents·2004
6-review
Transcription profiling of gene expression in drug discovery and development: the NCI experience.
PMID 15541957·Eur J Cancer·2004
6-review
Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
PMID 12678914·Curr Med Chem Anticancer Agents·2003
6-review
Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
PMID 14529389·Curr Cancer Drug Targets·2003
6-review
Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?
PMID 12727387·Lancet·2003
8-other
Complexities in the development of cyclin-dependent kinase inhibitor drugs.
PMID 11927285·Trends Mol Med·2002
6-review
International Society for Oncodevelopmental Biology and Medicine - XXXth Meeting.
PMID 14689934·IDrugs·2002
8-other
Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
PMID 11489788·Clin Cancer Res·2001
8-other
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
PMID 11304786·J Clin Oncol·2001
3-trial
Role of the National Cancer Institute in acquired immunodeficiency syndrome-related drug discovery.
PMID 11158208·J Natl Cancer Inst Monogr·2001
6-review
11th NCI-EORTC-AACR: New therapeutic targets, signal transduction and angiogenesis.
PMID 16032473·IDrugs·2001
8-other
The challenge of pathway and environment-mediated drug resistance.
PMID 11831639·Cancer Metastasis Rev·2001
6-review
Molecules for the millennium: how will they look? New drug discovery year 2000.
PMID 11076644·Br J Cancer·2000
6-review
Overview. Cancer drug discovery: pathway promise or covalent certainty for drug effect--quo vadis?
PMID 11249707·Curr Opin Investig Drugs·2000
6-review
Protein kinase antagonists: interim challenges and issues.
PMID 10888031·Anticancer Drug Des·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 22 S GREENE ST
BALTIMORE, MD 21201 - Phone
- (410) 328-7394
Quick Facts
- NPI
- 1528020393
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile